CG

Carol Gallagher

Experienced Board Director

Del Mar, California

Operator
Advisor

Invests in

  • Min Investment:

    $0.00

  • Max Investment:

    $0.00

  • Target Investment:

    $0.00

Skills

Biopharmaceuticals
Management
Product Launch
Strategy
Patents
Clinical Development
Drug Development
R&D
Pharmaceutical Industry
Oncology
Product Development
Biotechnology
Drug Discovery
Leadership
Biochemistry
Recruiting
Pharmaceutical Sales
Start-ups
Marketing
Cardiology

Education

Investments

Recludix Pharma

Series A

Total Funding: $60M

Millendo Therapeutics

Series B

Total Funding: $110M

Metacrine

Series B

Total Funding: $140M

Pionyr Immunotherapeutics

Series B

Total Funding: $79M

Good2Go, Inc

Seed

Total Funding: $7M

Good2Go, Inc.

Seed Round

Total Funding: $7M

Cleave Therapeutics

Series A

Total Funding: $100M

Work Experience

Self Employed

2024

  • Independent Board Director

    2024

New Enterprise Associates (NEA)

2014 - 2024

  • Venture Advisor

    2023 - 2024

  • Venture Partner

    2019 - 2023

  • Partner

    2014 - 2023

Calistoga Pharmaceuticals

2008 - 2011

  • Past President and CEO

    2008 - 2011

Metastatix, Inc.

2007 - 2008

  • President and CEO

    2007 - 2008

Anadys Pharmaceuticals

2006 - 2007

  • SVP, Corporate Development

    2006 - 2007

Anadys Pharmaceutcials

2006 - 2007

  • SVP, Corp Development

    2006 - 2007

CancerVax

2004 - 2006

  • VP, Sales, Markeitng, and Product Planning

    2004 - 2006

Biogen Idec

2002 - 2004

  • Director, Oncology Marketing and Rituxan Team Leader

    2002 - 2004

Idec Pharmaceuticals

2002 - 2003

  • Senior Director, Oncology Marketing

    2002 - 2003

Pfizer

2000 - 2001

  • Director, New Product Planning

    2000 - 2001